Literature DB >> 30974339

The assessment of resistance to antidepressant treatment: Rationale for the Antidepressant Treatment History Form: Short Form (ATHF-SF).

Harold A Sackeim1, Scott T Aaronson2, Mark T Bunker3, Charles R Conway4, Mark A Demitrack5, Mark S George6, Joan Prudic7, Michael E Thase8, A John Rush9.   

Abstract

There is considerable diversity in how treatment-resistant depression (TRD) is defined. However, every definition incorporates the concept that patients with TRD have not benefited sufficiently from one or more adequate trials of antidepressant treatment. This review examines the issues fundamental to the systematic evaluation of antidepressant treatment adequacy and resistance. These issues include the domains of interventions deemed effective in treatment of major depressive episodes (e.g., pharmacotherapy, brain stimulation, and psychotherapy), the subgroups of patients for whom distinct adequacy criteria are needed (e.g., bipolar vs. unipolar depression, psychotic vs. nonpsychotic depression), whether trials should be rated dichotomously as adequate or inadequate or on a potency continuum, whether combination and augmentation strategies require specific consideration, and the criteria used to evaluate the adequacy of treatment delivery (e.g., dose, duration), trial adherence, and clinical outcome. This review also presents the Antidepressant Treatment History Form: Short-Form (ATHF-SF), a completely revised version of an earlier instrument, and details how these fundamental issues were addressed in the ATHF-SF.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Antidepressant treatment resistance; Brain stimulation; Major depressive episode; Pharmacotherapy; Psychotherapy; Treatment-resistant depression

Mesh:

Substances:

Year:  2019        PMID: 30974339     DOI: 10.1016/j.jpsychires.2019.03.021

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  12 in total

Review 1.  Annual Research Review: Defining and treating pediatric treatment-resistant depression.

Authors:  Jennifer B Dwyer; Argyris Stringaris; David A Brent; Michael H Bloch
Journal:  J Child Psychol Psychiatry       Date:  2020-02-04       Impact factor: 8.982

Review 2.  Ketamine: Leading us into the future for development of antidepressants.

Authors:  Flavia R Carreno; Daniel J Lodge; Alan Frazer
Journal:  Behav Brain Res       Date:  2020-02-02       Impact factor: 3.332

3.  Distinct predictors of short- versus long-term depression outcomes following electroconvulsive therapy.

Authors:  Brian J Mickey; Yarden Ginsburg; Erica Jensen; Daniel F Maixner
Journal:  J Psychiatr Res       Date:  2021-12-14       Impact factor: 5.250

4.  A two-site, open-label, non-randomized trial comparing Focal Electrically-Administered Seizure Therapy (FEAST) and right unilateral ultrabrief pulse electroconvulsive therapy (RUL-UBP ECT).

Authors:  Gregory L Sahlem; William V McCall; E Baron Short; Peter B Rosenquist; James B Fox; Nagy A Youssef; Andrew J Manett; Suzanne E Kerns; Morgan M Dancy; Laryssa McCloud; Mark S George; Harold A Sackeim
Journal:  Brain Stimul       Date:  2020-07-29       Impact factor: 8.955

5.  Long-term quality of life in treatment-resistant depression after electroconvulsive therapy.

Authors:  Heidemarie Lex; Steven W Nevers; Erica L Jensen; Yarden Ginsburg; Daniel F Maixner; Brian J Mickey
Journal:  J Affect Disord       Date:  2021-05-18       Impact factor: 6.533

6.  The Effects of Focal Electrically Administered Seizure Therapy Compared With Ultrabrief Pulse Right Unilateral Electroconvulsive Therapy on Suicidal Ideation: A 2-Site Clinical Trial.

Authors:  Nagy A Youssef; Mark S George; William V McCall; Gregory L Sahlem; Baron Short; Suzanne Kerns; Andrew J Manett; James B Fox; Morgan Dancy; Daniel Cook; William Devries; Peter B Rosenquist; Harold A Sackeim
Journal:  J ECT       Date:  2021-12-01       Impact factor: 3.692

Review 7.  Management of Treatment-Resistant Depression: Challenges and Strategies.

Authors:  Daphne Voineskos; Zafiris J Daskalakis; Daniel M Blumberger
Journal:  Neuropsychiatr Dis Treat       Date:  2020-01-21       Impact factor: 2.570

Review 8.  The Long and Winding Road of Vagus Nerve Stimulation: Challenges in Developing an Intervention for Difficult-to-Treat Mood Disorders.

Authors:  Harold A Sackeim; Maxine Dibué; Mark T Bunker; A John Rush
Journal:  Neuropsychiatr Dis Treat       Date:  2020-12-14       Impact factor: 2.570

9.  Vagus nerve stimulation as adjunctive therapy in patients with difficult-to-treat depression (RESTORE-LIFE): study protocol design and rationale of a real-world post-market study.

Authors:  Allan H Young; Mario F Juruena; Renske De Zwaef; Koen Demyttenaere
Journal:  BMC Psychiatry       Date:  2020-09-29       Impact factor: 3.630

10.  Treatment of major depressive disorder with bilateral theta burst stimulation: study protocol for a randomized, double-blind, placebo-controlled multicenter trial (TBS-D).

Authors:  Christian Plewnia; Bettina Brendel; Tobias Schwippel; Vanessa Nieratschker; Thomas Ethofer; Thomas Kammer; Frank Padberg; Peter Martus; Andreas J Fallgatter
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-06-19       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.